HNB
BCRX icon

Huntington National Bank’s BioCryst Pharmaceuticals BCRX Stock Holding History

Huntington National Bank’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.7K Buy
8,480
+927
+12% +$7.2K ﹤0.01% 1158
2025
Q4 		$58.9K Buy
7,553
+917
+14% +$6.63K ﹤0.01% 1186
2025
Q3 		$50.4K Sell
6,636
-64
-1% -$533 ﹤0.01% 1254
2025
Q2 		$60K Buy
6,700
+100
+2% +$931 ﹤0.01% 1177
2025
Q1 		$49.5K Sell
6,600
-60
-0.9% -$484 ﹤0.01% 1181
2024
Q4 		$50.1K Sell
6,660
-81
-1% -$615 ﹤0.01% 1194
2024
Q3 		$51.2K Buy
6,741
+53
+0.8% +$403 ﹤0.01% 1165
2024
Q2 		$41.3K Sell
6,688
-25
-0.4% -$138 ﹤0.01% 1193
2024
Q1 		$34.1K Sell
6,713
-151
-2% -$849 ﹤0.01% 1265
2023
Q4 		$41.1K Buy
6,864
+12
+0.2% +$70 ﹤0.01% 1152
2023
Q3 		$48.5K Sell
6,852
-142
-2% -$1.02K ﹤0.01% 1052
2023
Q2 		$49.2K Buy
6,994
+311
+5% +$2.5K ﹤0.01% 1058
2023
Q1 		$55.7K Buy
6,683
+1,140
+21% +$11K ﹤0.01% 968
2022
Q4 		$63.6K Sell
5,543
-39
-0.7% -$486 ﹤0.01% 916
2022
Q3 		$70K Buy
5,582
+1,081
+24% +$13.9K ﹤0.01% 882
2022
Q2 		$48K Hold
4,501
– – ﹤0.01% 1010
2022
Q1 		$73K Hold
4,501
– – ﹤0.01% 941
2021
Q4 		$62K Hold
4,501
– – ﹤0.01% 1001
2021
Q3 		$65K Hold
4,501
– – ﹤0.01% 898
2021
Q2 		$71K Hold
4,501
– – ﹤0.01% 839
2021
Q1 		$46K Hold
4,501
– – ﹤0.01% 877
2020
Q4 		$34K Hold
4,501
– – ﹤0.01% 932
2020
Q3 		$15K Hold
4,501
– – ﹤0.01% 1133
2020
Q2 		$21K Hold
4,501
– – ﹤0.01% 1010
2020
Q1 		$9K Hold
4,501
– – ﹤0.01% 1215
2019
Q4 		$16K Hold
4,501
– – ﹤0.01% 1310
2019
Q3 		$13K Hold
4,501
– – ﹤0.01% 1217
2019
Q2 		$17K Buy
4,501
+1
+0% +$6 ﹤0.01% 1182
2019
Q1 		$37K Sell
4,500
-1
-0% -$9 ﹤0.01% 925
2018
Q4 		$36K Hold
4,501
– – ﹤0.01% 954
2018
Q3 		$34K Buy
4,501
+1
+0% +$7 ﹤0.01% 1086
2018
Q2 		$26K Buy
+4,500
New +$24.8K ﹤0.01% 1144

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Huntington National Bank's BCRX Position: Q1 2026 in Review

Huntington National Bank increased its BioCryst Pharmaceuticals (BCRX) stake by 12% in Q1 2026, buying an estimated $7.2K and bringing the position to 8,480 shares worth $80.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1158.

Huntington National Bank first reported a position in BCRX in Q2 2018 and has held it in 32 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Huntington National Bank held 8,480 shares of BioCryst Pharmaceuticals worth $80.7K as of Q1 2026.
  • Huntington National Bank bought 927 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $7.2K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #1158 holding.
  • Huntington National Bank first reported a position in BioCryst Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.